Profile - To The Moon

jovansim

Posts · 3Posts · 3
Following · 0Following · 0
Followers · 0Followers · 0

- jovansimjovansim
  ·2021-08-30
  godlike
  Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis
  Pfizer Inc :Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy O
  Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis
  238 Comment
  3
  Share
  Report
- jovansimjovansim
  ·2021-07-12
  wow
  Chase, Delta, Goldman Sachs, PepsiCo, and Other Stocks to Watch This Week
  Second-quarter earnings season gets under way this week, with several big banks reporting. JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,andCitigroupon Wednesday andMorgan Stanleyon Thursday.The week’s economic calendar will be equally busy. The Bureau of Labor Statistics releases the consumer price index for June on Tuesday, followed by the producer price index for June on Wednesday. Expectations are for year-over-year increases of 4.0% a
  Chase, Delta, Goldman Sachs, PepsiCo, and Other Stocks to Watch This Week
  173 2
  3
  Share
  Report
- jovansimjovansim
  ·2021-07-09
  cool man
  BioNTech shares rises 3.6% in premarket
  BioNTech shares rises 3.6% in premarket trading,which is developing a booster shot specifically targ
  BioNTech shares rises 3.6% in premarket
  91 Comment
  2
  Share
  Report
No following yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3584526700310105","uuid":"3584526700310105","gmtCreate":1621435000406,"gmtModify":1625821884824,"name":"jovansim","pinyin":"jovansim","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/0f3c300491805f20e8643c565850e7bb","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":13,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.84%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":10,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":811646489,"gmtCreate":1630321664841,"gmtModify":1676530267860,"author":{"id":"3584526700310105","authorId":"3584526700310105","name":"jovansim","avatar":"https://static.tigerbbs.com/0f3c300491805f20e8643c565850e7bb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584526700310105","authorIdStr":"3584526700310105"},"themes":[],"htmlText":"godlike","listText":"godlike","text":"godlike","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/811646489","repostId":"2163888743","repostType":2,"repost":{"id":"2163888743","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1630320528,"share":"https://ttm.financial/m/news/2163888743?lang=&edition=fundamental","pubTime":"2021-08-30 18:48","market":"us","language":"en","title":"Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2163888743","media":"T-Reuters","summary":"Pfizer Inc :Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy O","content":"<html><body><p>Pfizer Inc <pfe.n>:Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.Pfizer Inc - Jade Dare Trial Met Co-Primary And Key Secondary Endpoints And Demonstrated A Safety Profile Consistent With Previous Studies.Pfizer Inc - Study Showed That Abrocitinib Was Statistically Superior Compared To Dupilumab In Each Evaluated Efficacy Measure.</pfe.n></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPositive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-08-30 18:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Pfizer Inc <pfe.n>:Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.Pfizer Inc - Jade Dare Trial Met Co-Primary And Key Secondary Endpoints And Demonstrated A Safety Profile Consistent With Previous Studies.Pfizer Inc - Study Showed That Abrocitinib Was Statistically Superior Compared To Dupilumab In Each Evaluated Efficacy Measure.</pfe.n></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CGEM":"Cullinan Therapeutics","LHDX":"Lucira Health, Inc.","APR":"Apria, Inc.","SANA":"Sana Biotechnology, Inc.","PFE":"辉瑞","LABP":"Landos Biopharma, Inc."},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2163888743","content_text":"Pfizer Inc :Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis.Pfizer Inc - Jade Dare Trial Met Co-Primary And Key Secondary Endpoints And Demonstrated A Safety Profile Consistent With Previous Studies.Pfizer Inc - Study Showed That Abrocitinib Was Statistically Superior Compared To Dupilumab In Each Evaluated Efficacy Measure.","news_type":1},"isVote":1,"tweetType":1,"viewCount":238,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146025409,"gmtCreate":1626045790801,"gmtModify":1703752147637,"author":{"id":"3584526700310105","authorId":"3584526700310105","name":"jovansim","avatar":"https://static.tigerbbs.com/0f3c300491805f20e8643c565850e7bb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584526700310105","authorIdStr":"3584526700310105"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/146025409","repostId":"1114863871","repostType":4,"repost":{"id":"1114863871","pubTimestamp":1626039626,"share":"https://ttm.financial/m/news/1114863871?lang=&edition=fundamental","pubTime":"2021-07-12 05:40","market":"us","language":"en","title":"Chase, Delta, Goldman Sachs, PepsiCo, and Other Stocks to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1114863871","media":"Barron's","summary":"Second-quarter earnings season gets under way this week, with several big banks reporting. JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,andCitigroupon Wednesday andMorgan Stanleyon Thursday.The week’s economic calendar will be equally busy. The Bureau of Labor Statistics releases the consumer price index for June on Tuesday, followed by the producer price index for June on Wednesday. Expectations are for year-over-year increases of 4.0% a","content":"<p>Second-quarter earnings season gets under way&nbsp;this week, with several big banks reporting.&nbsp;JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,andCitigroupon Wednesday andMorgan Stanleyon Thursday.</p>\n<p>Other major companies reporting this week includePepsiCoandFastenalon Tuesday,Delta Air Lineson Wednesday,Taiwan Semiconductor ManufacturingandUnitedHealth Groupon Thursday, andKansas City Southernon Friday.</p>\n<p>The week’s economic calendar will be equally busy. The Bureau of Labor Statistics releases the consumer price index for June on Tuesday,&nbsp;followed by the producer price index for June on Wednesday. Expectations are for year-over-year increases of 4.0% and 6.4%, respectively, in the core CPI and core PPI.</p>\n<p>Investors and economists will also get a look at a pair of sentiment surveys this week:&nbsp;The National Federation of Independent Business’ Small Business Optimism Index for June on Tuesday and The University of Michigan’s Consumer Sentiment index for July on Friday. The&nbsp;Federal Reserve releases its latest beige book on Wednesday, the Census Bureau reports retail-sales data for June on Friday, and theBank of Japanannounces its latest monetary-policy decision on Friday.</p>\n<p><img src=\"https://static.tigerbbs.com/1508a89eaa3fb959feaaa832797a2c48\" tg-width=\"1176\" tg-height=\"360\"></p>\n<p><b>Monday 7/12</b></p>\n<p>FedExhosts a conference call to update the investment community on its business outlook.</p>\n<p><b>Tuesday 7/13</b></p>\n<p>JPMorgan Chase and Goldman Sachs Group kick off earnings season by reporting results before the market open. The two money-center banks recently lifted their dividends 11% and 60%, respectively.</p>\n<p>Conagra Brands,Fastenal,First Republic Bank,and PepsiCo report quarterly results.</p>\n<p>Dell Technologieshosts a conference call to discuss its ESG strategy.</p>\n<p><b>The Bureau of Labor</b>&nbsp;Statistics releases the consumer price index for June. Economists forecast a 4.9% year-over-year rise, after a 5% jump in May—the fastest rate of growth since August 2008. The core CPI, which excludes volatile food and energy prices, is expected to increase 4% compared with 3.8% previously.</p>\n<p><b>The National Federation</b>&nbsp;of Independent Business releases its Small Business Optimism Index for June. Consensus estimate is for a 99.5 reading, about even with the May figure.</p>\n<p><b>Wednesday 7/14</b></p>\n<p>Bank of America,BlackRock,Citigroup, Delta Air Lines,PNC Financial Services Group,and Wells Fargo release earnings.</p>\n<p><b>The Federal Reserve</b>&nbsp;releases the beige book for the fifth of eight times this year. The report gathers anecdotal evidence of current economic conditions in the 12 Federal Reserve districts.</p>\n<p><b>The BLS releases</b>&nbsp;the producer price index for June. Expectations are for both the PPI and core PPI to increase 0.5% month over month. This compares with gains of 0.8% and 0.7%, respectively, in May.</p>\n<p><b>Thursday 7/15</b></p>\n<p>Bank of New York Mellon,Cintas,Morgan Stanley, Taiwan Semiconductor Manufacturing,Truist Financial,U.S. Bancorp,and UnitedHealth Group hold conference calls to discuss quarterly results.</p>\n<p><b>Friday 7/16</b></p>\n<p>Charles Schwab,Ericsson,Kansas City Southern, andState Streetannounce earnings.</p>\n<p><b>The Bank of Japan</b>&nbsp;announces its monetary-policy decision. The central bank is widely expected to keep its key short-term interest rate unchanged at negative 0.1%. In June, the BOJ said it would launch a climate-change plan by the end of this year, and would release a preliminary plan at its July meeting. This could take the form of higher interest rates paid to banks for green-lending measures.</p>\n<p><b>The University of Michigan</b>&nbsp;releases its Consumer Sentiment index for July. Economists forecast an 86.5 reading, slightly higher than June’s 85.5. The index is still well below its levels from just prior to the pandemic.</p>\n<p><b>The Census Bureau</b>&nbsp;reports retail-sales data for June. Consensus estimate is for a 0.5% monthly decline in spending to $617 billion, after slumping 1.3% in May.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chase, Delta, Goldman Sachs, PepsiCo, and Other Stocks to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChase, Delta, Goldman Sachs, PepsiCo, and Other Stocks to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-12 05:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-for-investors-to-watch-this-week-51625883421><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Second-quarter earnings season gets under way this week, with several big banks reporting. JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-for-investors-to-watch-this-week-51625883421\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MS":"摩根士丹利","JPM":"摩根大通","C":"花旗","BAC":"美国银行","TSM":"台积电","WFC":"富国银行","GS":"高盛"},"source_url":"https://www.barrons.com/articles/stocks-for-investors-to-watch-this-week-51625883421","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114863871","content_text":"Second-quarter earnings season gets under way this week, with several big banks reporting. JPMorgan ChaseandGoldman SachsGroup kick things off on Tuesday, followed byBank of America,Wells Fargo,andCitigroupon Wednesday andMorgan Stanleyon Thursday.\nOther major companies reporting this week includePepsiCoandFastenalon Tuesday,Delta Air Lineson Wednesday,Taiwan Semiconductor ManufacturingandUnitedHealth Groupon Thursday, andKansas City Southernon Friday.\nThe week’s economic calendar will be equally busy. The Bureau of Labor Statistics releases the consumer price index for June on Tuesday, followed by the producer price index for June on Wednesday. Expectations are for year-over-year increases of 4.0% and 6.4%, respectively, in the core CPI and core PPI.\nInvestors and economists will also get a look at a pair of sentiment surveys this week: The National Federation of Independent Business’ Small Business Optimism Index for June on Tuesday and The University of Michigan’s Consumer Sentiment index for July on Friday. The Federal Reserve releases its latest beige book on Wednesday, the Census Bureau reports retail-sales data for June on Friday, and theBank of Japanannounces its latest monetary-policy decision on Friday.\n\nMonday 7/12\nFedExhosts a conference call to update the investment community on its business outlook.\nTuesday 7/13\nJPMorgan Chase and Goldman Sachs Group kick off earnings season by reporting results before the market open. The two money-center banks recently lifted their dividends 11% and 60%, respectively.\nConagra Brands,Fastenal,First Republic Bank,and PepsiCo report quarterly results.\nDell Technologieshosts a conference call to discuss its ESG strategy.\nThe Bureau of Labor Statistics releases the consumer price index for June. Economists forecast a 4.9% year-over-year rise, after a 5% jump in May—the fastest rate of growth since August 2008. The core CPI, which excludes volatile food and energy prices, is expected to increase 4% compared with 3.8% previously.\nThe National Federation of Independent Business releases its Small Business Optimism Index for June. Consensus estimate is for a 99.5 reading, about even with the May figure.\nWednesday 7/14\nBank of America,BlackRock,Citigroup, Delta Air Lines,PNC Financial Services Group,and Wells Fargo release earnings.\nThe Federal Reserve releases the beige book for the fifth of eight times this year. The report gathers anecdotal evidence of current economic conditions in the 12 Federal Reserve districts.\nThe BLS releases the producer price index for June. Expectations are for both the PPI and core PPI to increase 0.5% month over month. This compares with gains of 0.8% and 0.7%, respectively, in May.\nThursday 7/15\nBank of New York Mellon,Cintas,Morgan Stanley, Taiwan Semiconductor Manufacturing,Truist Financial,U.S. Bancorp,and UnitedHealth Group hold conference calls to discuss quarterly results.\nFriday 7/16\nCharles Schwab,Ericsson,Kansas City Southern, andState Streetannounce earnings.\nThe Bank of Japan announces its monetary-policy decision. The central bank is widely expected to keep its key short-term interest rate unchanged at negative 0.1%. In June, the BOJ said it would launch a climate-change plan by the end of this year, and would release a preliminary plan at its July meeting. This could take the form of higher interest rates paid to banks for green-lending measures.\nThe University of Michigan releases its Consumer Sentiment index for July. Economists forecast an 86.5 reading, slightly higher than June’s 85.5. The index is still well below its levels from just prior to the pandemic.\nThe Census Bureau reports retail-sales data for June. Consensus estimate is for a 0.5% monthly decline in spending to $617 billion, after slumping 1.3% in May.","news_type":1},"isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141009823,"gmtCreate":1625821394462,"gmtModify":1703749242367,"author":{"id":"3584526700310105","authorId":"3584526700310105","name":"jovansim","avatar":"https://static.tigerbbs.com/0f3c300491805f20e8643c565850e7bb","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584526700310105","authorIdStr":"3584526700310105"},"themes":[],"htmlText":"cool man","listText":"cool man","text":"cool man","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/141009823","repostId":"1180424186","repostType":4,"repost":{"id":"1180424186","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625819933,"share":"https://ttm.financial/m/news/1180424186?lang=&edition=fundamental","pubTime":"2021-07-09 16:38","market":"us","language":"en","title":"BioNTech shares rises 3.6% in premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=1180424186","media":"Tiger Newspress","summary":"BioNTech shares rises 3.6% in premarket trading,which is developing a booster shot specifically targ","content":"<p>BioNTech&nbsp;shares&nbsp;rises 3.6% in premarket&nbsp;trading,which&nbsp;is&nbsp;developing a booster shot specifically targeting the so-called delta variant of the virus that causes the disease.</p>\n<p><img src=\"https://static.tigerbbs.com/f41726c12e31bc4f3b7aaaf7cfbf1ac5\" tg-width=\"1281\" tg-height=\"605\">Pfizer Inc. and COVID-19 vaccine partner BioNTech said late Thursday they are developing a booster shot specifically targeting the so-called delta variant of the virus that causes the disease.</p>\n<p>The Wall Street Journal reported saying fully vaccinated Americans \"do not need a booster shot at this time,\" but that they are prepared for booster doses \"if and when the science demonstrates they are needed.\"</p>\n<p>Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and BioNTech <a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a> said in a statement that there is encouraging data from the use of a third booster shot of their current BNT162b2 vaccine, which is widely administered in two doses given three weeks apart.</p>\n<p>\"While we believe a third dose of BNT162b2 has the potential to preserve the highest levels protective efficacy against all currently known variants including delta, we are remaining vigilant and are developing an updated version of the Pfizer-COVID-19 vaccine that uses a new construct based on the B.1.617.2 lineage, first identified in India and also known as the delta variant,\" the companies said in a statement.</p>\n<p>The companies also pointed to evidence from the Israeli Ministry of Health showing the effectiveness of the vaccine declined six months after the shots, just as the delta variant is taking hold in the country.</p>\n<p>Pfizer and BioNTech expect to begin clinical trials to study a third dose in August.</p>\n<p>\"That is why we have said, and we continue to believe, that it is likely, based on the totality of the data we have to date, that a third dose may be needed within 6 to 12 months after full vaccination,\" the companies said.</p>\n<p>On Thursday, Japan barred spectators from the Tokyo Olympics because of an uptick in COVID cases likely caused by the delta variant. Previously, only foreign spectators had been banned from attending the games in person.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech shares rises 3.6% in premarket</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech shares rises 3.6% in premarket\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-09 16:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;shares&nbsp;rises 3.6% in premarket&nbsp;trading,which&nbsp;is&nbsp;developing a booster shot specifically targeting the so-called delta variant of the virus that causes the disease.</p>\n<p><img src=\"https://static.tigerbbs.com/f41726c12e31bc4f3b7aaaf7cfbf1ac5\" tg-width=\"1281\" tg-height=\"605\">Pfizer Inc. and COVID-19 vaccine partner BioNTech said late Thursday they are developing a booster shot specifically targeting the so-called delta variant of the virus that causes the disease.</p>\n<p>The Wall Street Journal reported saying fully vaccinated Americans \"do not need a booster shot at this time,\" but that they are prepared for booster doses \"if and when the science demonstrates they are needed.\"</p>\n<p>Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and BioNTech <a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a> said in a statement that there is encouraging data from the use of a third booster shot of their current BNT162b2 vaccine, which is widely administered in two doses given three weeks apart.</p>\n<p>\"While we believe a third dose of BNT162b2 has the potential to preserve the highest levels protective efficacy against all currently known variants including delta, we are remaining vigilant and are developing an updated version of the Pfizer-COVID-19 vaccine that uses a new construct based on the B.1.617.2 lineage, first identified in India and also known as the delta variant,\" the companies said in a statement.</p>\n<p>The companies also pointed to evidence from the Israeli Ministry of Health showing the effectiveness of the vaccine declined six months after the shots, just as the delta variant is taking hold in the country.</p>\n<p>Pfizer and BioNTech expect to begin clinical trials to study a third dose in August.</p>\n<p>\"That is why we have said, and we continue to believe, that it is likely, based on the totality of the data we have to date, that a third dose may be needed within 6 to 12 months after full vaccination,\" the companies said.</p>\n<p>On Thursday, Japan barred spectators from the Tokyo Olympics because of an uptick in COVID cases likely caused by the delta variant. Previously, only foreign spectators had been banned from attending the games in person.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180424186","content_text":"BioNTech shares rises 3.6% in premarket trading,which is developing a booster shot specifically targeting the so-called delta variant of the virus that causes the disease.\nPfizer Inc. and COVID-19 vaccine partner BioNTech said late Thursday they are developing a booster shot specifically targeting the so-called delta variant of the virus that causes the disease.\nThe Wall Street Journal reported saying fully vaccinated Americans \"do not need a booster shot at this time,\" but that they are prepared for booster doses \"if and when the science demonstrates they are needed.\"\nPfizer $(PFE)$ and BioNTech $(BNTX)$ said in a statement that there is encouraging data from the use of a third booster shot of their current BNT162b2 vaccine, which is widely administered in two doses given three weeks apart.\n\"While we believe a third dose of BNT162b2 has the potential to preserve the highest levels protective efficacy against all currently known variants including delta, we are remaining vigilant and are developing an updated version of the Pfizer-COVID-19 vaccine that uses a new construct based on the B.1.617.2 lineage, first identified in India and also known as the delta variant,\" the companies said in a statement.\nThe companies also pointed to evidence from the Israeli Ministry of Health showing the effectiveness of the vaccine declined six months after the shots, just as the delta variant is taking hold in the country.\nPfizer and BioNTech expect to begin clinical trials to study a third dose in August.\n\"That is why we have said, and we continue to believe, that it is likely, based on the totality of the data we have to date, that a third dose may be needed within 6 to 12 months after full vaccination,\" the companies said.\nOn Thursday, Japan barred spectators from the Tokyo Olympics because of an uptick in COVID cases likely caused by the delta variant. Previously, only foreign spectators had been banned from attending the games in person.","news_type":1},"isVote":1,"tweetType":1,"viewCount":91,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}